
    
      This is an open-label single-arm trial to evaluate the efficacy of Rifaximin in patients with
      active microscopic colitis (MC). 10 subjects will be asked to take 500mg Rifaximin three
      times per day for 4 weeks. The primary endpoints will be histologic response and clinical
      remission (less than 3 stools per day and less than 1 watery stool per day within the prior 7
      days. The secondary endpoint will be change of the MC Disease Activity Index (MCDAI).
    
  